Standards of treatment in chronic hepatitis C

被引:0
作者
Gish, RG
机构
[1] Calif Pacific Med Ctr, Div Gastroenterol, Dept Med, San Francisco, CA 94115 USA
[2] Calif Pacific Med Ctr, Div Gastroenterol, Dept Transplantat, San Francisco, CA 94115 USA
关键词
chronic hepatitis C; interferon alpha; ribavirin;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Standards of treatment for patients who are infected with the hepatitis C virus have been developed from national and international consensus conferences, from extensive clinical experience with various regimens, from exhaustive literature reviews, and from opinion lenders in the general medical community From 1987 until very recently, the standard of treatment for non-A, non-B hepatitis, later defined as hepatitis C, had consisted of alpha interferon monotherapy administered for up to 18 to 24 months. Alpha interferon has been used in a variety of regimens with varying success for the initial treatment of chronic hepatitis C, for the retreatment of patients who have relapsed after responding to interferon, and for the retreatment of alpha interferon nonresponders. Treatment standards have evolved as new agents have become available for use in our treatment armamentarium. The current treatment standards, as well as recommendations for the treatment of specific HCV subgroups, are reviewed.
引用
收藏
页码:35 / 47
页数:13
相关论文
共 196 条
[31]   LONGITUDINAL-STUDY OF HEPATITIS-C VIREMIA IN CHRONIC HEPATITIS-C [J].
CHEUNG, RC ;
CHAN, RT ;
LOK, ASF .
JOURNAL OF MEDICAL VIROLOGY, 1993, 41 (04) :338-342
[32]   ISOLATION OF A CDNA CLONE DERIVED FROM A BLOOD-BORNE NON-A, NON-B VIRAL-HEPATITIS GENOME [J].
CHOO, QL ;
KUO, G ;
WEINER, AJ ;
OVERBY, LR ;
BRADLEY, DW ;
HOUGHTON, M .
SCIENCE, 1989, 244 (4902) :359-362
[33]   EFFECT OF IRON OVERLOAD ON THE RESPONSE TO RECOMBINANT INTERFERON-ALFA TREATMENT IN TRANSFUSION-DEPENDENT PATIENTS WITH THALASSEMIA MAJOR AND CHRONIC HEPATITIS-C [J].
CLEMENTE, MG ;
CONGIA, M ;
LAI, ME ;
LILLIU, F ;
LAMPIS, R ;
FRAU, F ;
FRAU, MR ;
FAA, G ;
DIANA, G ;
DESSI, C ;
MELIS, A ;
MAZZOLENI, AP ;
CORNACCHIA, G ;
CAO, A ;
DEVIRGILIIS, S .
JOURNAL OF PEDIATRICS, 1994, 125 (01) :123-128
[34]   Extrahepatic immunologic features of chronic viral hepatitis [J].
Czaja, AJ .
DIGESTIVE DISEASES, 1997, 15 (03) :125-144
[35]   FREQUENCY AND SIGNIFICANCE OF ANTIBODY TO HEPATITIS-C VIRUS IN SEVERE CORTICOSTEROID-TREATED AUTOIMMUNE CHRONIC ACTIVE HEPATITIS [J].
CZAJA, AJ ;
TASWELL, HF ;
RAKELA, J ;
SCHIMEK, CM .
MAYO CLINIC PROCEEDINGS, 1991, 66 (06) :572-582
[36]   Factors predictive of a beneficial response to therapy of hepatitis C [J].
Davis, GL ;
Lau, JYN .
HEPATOLOGY, 1997, 26 (03) :S122-S127
[37]   Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C [J].
Davis, GL ;
Esteban-Mur, R ;
Rustgi, V ;
Hoefs, J ;
Gordon, SC ;
Trepo, C ;
Shiffman, ML ;
Zeuzem, S ;
Craxi, A ;
Ling, MH ;
Albrecht, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1493-1499
[38]   INTERFERON TREATMENT OF VIRAL-HEPATITIS IN IMMUNOCOMPROMISED PATIENTS [J].
DAVIS, GL .
SEMINARS IN LIVER DISEASE, 1989, 9 (04) :267-272
[39]   T-LYMPHOCYTES AND IRON OVERLOAD - NOVEL CORRELATIONS OF POSSIBLE SIGNIFICANCE TO THE BIOLOGY OF THE IMMUNOLOGICAL SYSTEM [J].
DESOUSA, M .
MEMORIAS DO INSTITUTO OSWALDO CRUZ, 1992, 87 :23-29
[40]   PROGNOSTIC FACTORS FOR ALL-CAUSE MORTALITY AMONG HEMOPHILIACS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS [J].
DIAMONDSTONE, LS ;
BLAKLEY, SA ;
RICE, JC ;
CLARK, RA ;
GOEDERT, JJ .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1995, 142 (03) :304-313